At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
40um Embozene TANDEM Microspheresdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy: A Pilot Study of Irinotecan in the Treatment of Metastatic Colorectal Carcinoma (mCRC) by Embozene TANDEM™ Drug-Eluting Microspheres Embolization
In Brief
A clinical study evaluating 40um Embozene TANDEM Microspheres for Colorectal Carcinoma. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The purpose of this study is to determine safety and local tumor control of Embozene TANDEM Microspheres (40um TANDEM) loaded with Irinotecan to treat metastatic colorectal carcinoma (mCRC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Carcinoma
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedFeb 2016
Primary CompletionDec 2016
TodayJul 2026
First PostedFeb 29, 2016
Enrollment StartNov 1, 2013
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.3 years ago
Interventions
40um Embozene TANDEM Microspheresdevice
40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).